The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...

The U.S. is seeing a "quad-demic" as cases of COVID-19, flu, RSV and norovirus spread at the same time. Experts said this is ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The Health Protection Surveillance Centre (HPSC) has reported a further reduction in cases of flu, the Respiratory Syncytial ...

At the start of every week, our team talks with local experts to unpack a wide range of nationwide health, safety, and ...

UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...

Wales is past the peak of its flu season according to public health bosses. Cases of flu have caused chaos in Wales' ...